申请人:MOCHIDA PHARMACEUTICAL CO., LTD.
公开号:EP0670315A1
公开(公告)日:1995-09-06
Triazole oxime derivatives represented by the formula (I):
(where Ar is a phenyl group substituted by 1 or 2 halogen atoms; R¹ and R² are typically such that, when taken together with the adjacent carbon atom, they form a cyclopropylidene group; R³ is a straight-chained, branched or cyclic alkyl group having 1 - 4 carbon atoms; R⁴ is typically an optionally substituted straight-chained or branched alkyl group having 1 - 4 carbon atoms; and the wavy line represents either an E- or Z-type bond) or salts thereof. The triazole derivatives exhibit a marked therapeutic effects not only in in vitro experiments but also in in vivo experiments using laboratory animal models such as Aspergillus infected mice. The derivatives are also safe to use. Therefore, they are extremely useful as therapeutics for various superficial dermatomycoses, deep dermatomycoses and deep mycoses (mycoses in internal organs).
Triazole oxime 衍生物的化学式(I)表示为:
(其中 Ar 是一个被 1 或 2 个卤素原子取代的苯基;R¹ 和 R² 通常是这样的,当与相邻的碳原子一起时,它们形成一个环丙烯基团;R³ 是一个直链、支链或环状的含有 1 - 4 个碳原子的烷基团;R⁴ 通常是一个可选择取代的直链或支链烷基团,含有 1 - 4 个碳原子;波浪线代表 E- 或 Z- 类型键)或其盐。这些三唑衍生物不仅在体外实验中表现出显著的治疗效果,而且在使用实验动物模型(如感染曲霉的小鼠)进行体内实验时也表现出显著的治疗效果。这些衍生物也是安全的。因此,它们在治疗各种浅表真菌病、深部真菌病和深部真菌病(内脏器官真菌病)方面非常有用。